Foamable pharmaceutical compositions and methods for treating a disorder
A kind of mixture, pharmaceutical technology, applied in the diseases of skin and mucous membranes, delivery of foamable pharmaceutical composition, preparation of foamable pharmaceutical composition, can solve the problems such as harmful foam stability
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
preparation example Construction
[0352] Other acids known to be useful in the preparation of foamable compositions are also within the scope of the present invention.
[0353] Acids for inclusion in the compositions of the present invention are selected to maintain the pH of the composition suitably in the range of about 2 to about 10. Depending on the particular active therapeutic agent contained in the composition, the optimum pH of the composition, the acid used to maintain the optimum pH and the amount of acid will vary. As will be appreciated, the selection of the optimum pH for each particular active agent, and the optimum type and amount of acid to achieve that optimum pH, is within the ordinary knowledge of those of ordinary skill in the art.
[0354] other ingredients
[0355] In addition to the active therapeutic agent and the foamable delivery system, the pharmaceutical formulations of the present invention may contain other non-essential optional ingredients suitable for topical foams known to th...
Embodiment 1
[0473] The following examples illustrate the preparation of the foamable pharmaceutical composition that is the subject of the present invention:
[0474] weight percentage (%)
[0475] Clobetasol Propionate 0.05
[0476] Poloxamer 188 1.60
[0477] Citric acid buffer 0.15
[0478] Ethanol 60.0
[0479] Polysorbate 60 0.10
[0480] Propylene glycol 2.00
[0481] Purified water 31.6
[0482] Propellant (propane-isobutane) 4.50
[0483] 100.0%
[0484] Preparation of the composition:
[0485] 1. The raw materials other than the propellant are mixed by conventional means to form an aerosol concentrate.
[0486] 2. The concentrate is then filled into aerosol containers such as aluminum tubes.
[0487] 3. The propellant is then added via conventional procedures such as fill through valve or under cup fill.
Embodiment 2
[0489] The following examples illustrate the preparation of the foamable pharmaceutical composition that is the subject of the present invention:
[0490] weight percentage (%)
[0491] Betamethasone valerate 0.10
[0492] Laureth-4 3.00
[0493] Phosphate buffer 0.20
[0494] Ethanol 65.0
[0495] Sodium diethylhexyl succinate 1.00
[0496] Glycerin 3.00
[0497] Purified water 23.4
[0498] Propellant (propane-isobutane) 4.30
[0499] 100.0%
[0500] Preparation of the composition:
[0501] 1. The raw materials other than the propellant are mixed by conventional means to form an aerosol concentrate.
[0502] 2. The concentrate is then filled into aerosol containers such as aluminum tubes.
[0503] 3. The propellant is then added via conventional procedures such as fill through valve or under cup fill.
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 